These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 24819214)
1. Mycobacterium tuberculosis persistence in various adipose depots of infected mice and the effect of anti-tubercular therapy. Agarwal P; Khan SR; Verma SC; Beg M; Singh K; Mitra K; Gaikwad AN; Akhtar MS; Krishnan MY Microbes Infect; 2014 Jul; 16(7):571-80. PubMed ID: 24819214 [TBL] [Abstract][Full Text] [Related]
2. Is adipose tissue a place for Mycobacterium tuberculosis persistence? Neyrolles O; Hernández-Pando R; Pietri-Rouxel F; Fornès P; Tailleux L; Barrios Payán JA; Pivert E; Bordat Y; Aguilar D; Prévost MC; Petit C; Gicquel B PLoS One; 2006 Dec; 1(1):e43. PubMed ID: 17183672 [TBL] [Abstract][Full Text] [Related]
3. Mycobacterium tuberculosis can gain access to adipose depots of mice infected via the intra-nasal route and to lungs of mice with an infected subcutaneous fat implant. Agarwal P; Pandey P; Sarkar J; Krishnan MY Microb Pathog; 2016 Apr; 93():32-7. PubMed ID: 26792675 [TBL] [Abstract][Full Text] [Related]
4. Bouzid F; Brégeon F; Poncin I; Weber P; Drancourt M; Canaan S Front Cell Infect Microbiol; 2017; 7():189. PubMed ID: 28567368 [TBL] [Abstract][Full Text] [Related]
8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)]. Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898 [TBL] [Abstract][Full Text] [Related]
9. Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development. Le Chevalier F; Cascioferro A; Majlessi L; Herrmann JL; Brosch R Future Microbiol; 2014; 9(8):969-85. PubMed ID: 25302954 [TBL] [Abstract][Full Text] [Related]
10. Adipocyte Model of Mycobacterium tuberculosis Infection Reveals Differential Availability of Iron to Bacilli in the Lipid-Rich Caseous Environment. Nandy A; Mondal AK; Pandey R; Arumugam P; Dawa S; Jaisinghani N; Rao V; Dash D; Gandotra S Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632245 [No Abstract] [Full Text] [Related]
11. Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. Beamer G; Major S; Das B; Campos-Neto A Am J Pathol; 2014 Dec; 184(12):3170-5. PubMed ID: 25451154 [TBL] [Abstract][Full Text] [Related]
12. The secret trumps, impelling the pathogenicity of tubercle bacilli. Cardona PJ; Ivanyi J Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():14-9. PubMed ID: 21420562 [TBL] [Abstract][Full Text] [Related]
13. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. Ahmad Z; Sharma S; Khuller GK FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718 [TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis. Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis. Mata-Espinosa D; Molina-Salinas GM; Barrios-Payán J; Navarrete-Vázquez G; Marquina B; Ramos-Espinosa O; Bini EI; Baeza I; Hernández-Pando R Pulm Pharmacol Ther; 2015 Jun; 32():7-14. PubMed ID: 25843004 [TBL] [Abstract][Full Text] [Related]
16. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size. de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760 [TBL] [Abstract][Full Text] [Related]
17. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Nikonenko BV; Samala R; Einck L; Nacy CA Antimicrob Agents Chemother; 2004 Dec; 48(12):4550-5. PubMed ID: 15561824 [TBL] [Abstract][Full Text] [Related]
18. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Faujdar J; Gupta P; Natrajan M; Das R; Chauhan DS; Katoch VM; Gupta UD Indian J Med Res; 2011 Nov; 134(5):696-703. PubMed ID: 22199110 [TBL] [Abstract][Full Text] [Related]
19. TB drug development: immunology at the table. Nathan C; Barry CE Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568 [TBL] [Abstract][Full Text] [Related]
20. Viral gene expression in HIV transgenic mice is activated by Mycobacterium tuberculosis and suppressed after antimycobacterial chemotherapy. Scanga CA; Bafica A; Sher A J Infect Dis; 2007 Jan; 195(2):246-54. PubMed ID: 17191170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]